Kriel Magdalena, Davidson Alan, Pillay Komala, Hendricks Marc, Phillips Lee-Ann
Division of Haematology, National Health Laboratory Service (NHLS), Groote Schuur Hospital and the University of Cape Town.
Haematology-Oncology Service, Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital and the University of Cape Town.
J Pediatr Hematol Oncol. 2020 May;42(4):e219-e227. doi: 10.1097/MPH.0000000000001709.
We characterized B-cell non-Hodgkin lymphoma (NHL) cases over 10 years at a tertiary children's hospital to contribute to the body of knowledge on pediatric lymphoma in developing countries with a high human immunodeficiency virus (HIV) burden.
A retrospective cohort study was carried out using clinical and laboratory records of children newly diagnosed with B-cell NHL from January 2005 to December 2014.
Seventy-five children ≤15 years of age were included. The majority had Burkitt lymphoma (n=61). Overall, (n=19) were HIV positive and 16% (n=12) had concurrent active tuberculosis. Bulky disease was present in 65.7% (n=46) and 30.1% (n=22) were classified as Lymphomes Malins B risk group C. The 5-year survival estimates for HIV-negative and HIV-positive children were similar in our cohort: 81% versus 79% for event-free survival and 85% versus 83.9% for overall survival. Of 3 children with Burkitt lymphoma, HIV, and Lymphomes Malins B group C, 2 died within 1 year.
Irrespective of HIV status, the survival of children in our B-cell NHL cohort compares favorably with cure rates in developed nations, although advanced disease remains associated with a poor prognosis. Characterization of childhood NHL cases contributes to accurate risk stratification and tailored treatment.
我们对一家三级儿童医院10年间的B细胞非霍奇金淋巴瘤（NHL）病例进行了特征分析，以丰富在人类免疫缺陷病毒（HIV）负担较高的发展中国家有关儿童淋巴瘤的知识体系。
采用2005年1月至2014年12月新诊断为B细胞NHL的儿童的临床和实验室记录进行回顾性队列研究。
纳入了75名15岁及以下儿童。大多数患有伯基特淋巴瘤（n = 61）。总体而言，19名（n = 19）为HIV阳性，16%（n = 12）同时患有活动性结核病。65.7%（n = 46）存在大包块病变，30.1%（n = 22）被归类为B组恶性淋巴瘤风险C组。在我们的队列中，HIV阴性和HIV阳性儿童的5年生存估计相似：无事件生存率分别为81%和79%，总生存率分别为85%和83.9%。在3名患有伯基特淋巴瘤、HIV和B组恶性淋巴瘤的儿童中，2名在1年内死亡。
无论HIV状态如何，我们队列中B细胞NHL儿童的生存率与发达国家的治愈率相比具有优势，尽管晚期疾病仍然预后不良。儿童NHL病例的特征分析有助于准确的风险分层和个性化治疗。
